Poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors are designed to exploit the “synthetic lethality” concept for cancer therapy.
Ryan P. Roop, MD
Advertisement
Articles by Ryan P. Roop, MD
Advertisement
Latest Updated Articles
- PARP Inhibitors and Their Evolving Role in Breast Cancer
Published: October 12th 2011 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
2
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
3
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
4
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
5
